CA2909500C - Crystal form of cabazitaxel and preparation method thereof - Google Patents

Crystal form of cabazitaxel and preparation method thereof Download PDF

Info

Publication number
CA2909500C
CA2909500C CA2909500A CA2909500A CA2909500C CA 2909500 C CA2909500 C CA 2909500C CA 2909500 A CA2909500 A CA 2909500A CA 2909500 A CA2909500 A CA 2909500A CA 2909500 C CA2909500 C CA 2909500C
Authority
CA
Canada
Prior art keywords
cabazitaxel
crystalline form
carbon atoms
mixture
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909500A
Other languages
English (en)
French (fr)
Other versions
CA2909500A1 (en
Inventor
Jing Li
Quanxing Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Sintaho Pharmaceutical Co Ltd
Original Assignee
Chongqing Taihao Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Taihao Pharmaceutical Co Ltd filed Critical Chongqing Taihao Pharmaceutical Co Ltd
Publication of CA2909500A1 publication Critical patent/CA2909500A1/en
Application granted granted Critical
Publication of CA2909500C publication Critical patent/CA2909500C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
CA2909500A 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof Active CA2909500C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210259595.3A CN102746258B (zh) 2012-07-25 2012-07-25 卡巴他赛的结晶形式及其制备方法
CN201210259595.3 2012-07-25
CA2870569A CA2870569A1 (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof
PCT/CN2013/079575 WO2014015760A1 (zh) 2012-07-25 2013-07-18 卡巴他赛的结晶形式及其制备方法
WOPCT/CN2013/079575 2013-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2870569A Division CA2870569A1 (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof

Publications (2)

Publication Number Publication Date
CA2909500A1 CA2909500A1 (en) 2014-01-30
CA2909500C true CA2909500C (en) 2018-01-09

Family

ID=47026807

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2909500A Active CA2909500C (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof
CA2870569A Abandoned CA2870569A1 (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2870569A Abandoned CA2870569A1 (en) 2012-07-25 2013-07-18 Crystal form of cabazitaxel and preparation method thereof

Country Status (8)

Country Link
US (1) US9353076B2 (enExample)
EP (2) EP3067348A1 (enExample)
JP (1) JP6329135B2 (enExample)
CN (1) CN102746258B (enExample)
AU (2) AU2013295924B2 (enExample)
CA (2) CA2909500C (enExample)
IN (1) IN2014MN01962A (enExample)
WO (1) WO2014015760A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012142117A1 (en) 2011-04-12 2012-10-18 Plus Chemicals Sa Solid state forms of cabazitaxel and processes for preparation thereof
US9394266B2 (en) 2012-03-08 2016-07-19 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103819428B (zh) * 2012-11-19 2016-01-13 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
KR101429543B1 (ko) 2012-12-13 2014-08-14 주식회사 삼양바이오팜 카바지탁셀의 신규 결정형 및 그 제조방법
CN103044364B (zh) * 2013-01-07 2016-01-20 重庆泰濠制药有限公司 一种卡巴他赛无定形晶及其制备方法
WO2014128728A2 (en) * 2013-02-25 2014-08-28 Laurus Labs Private Limited Solid forms of cabazitaxel and processes for preparation thereof
CN103450119B (zh) * 2013-09-24 2015-06-17 天津炜捷制药有限公司 一种卡巴他赛晶型w及其制备方法
EP2865674A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN105461665A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n6型物质及制备方法和其组合物与用途
CN105461664A (zh) * 2014-08-21 2016-04-06 中国医学科学院药物研究所 卡巴他赛晶n5型物质及制备方法和其组合物与用途
AU2017207821A1 (en) 2016-01-15 2018-07-19 Zhuhai Beihai Biotech Co., Ltd. Compositions and formulations including cabazitaxel and human serum albumin
EP3509569A1 (en) * 2016-09-07 2019-07-17 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
CN112055588B (zh) 2018-04-20 2023-09-08 珠海贝海生物技术有限公司 卡巴他赛的制剂和组合物
CN113429369B (zh) * 2021-07-23 2022-12-02 无锡紫杉药业有限公司 一种高效的卡巴他赛纯化方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
CN101525321B (zh) * 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
PL388144A1 (pl) * 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
CN102060815B (zh) * 2010-12-24 2012-09-26 重庆泰濠制药有限公司 一种紫杉烷类化合物的制备方法
WO2012142117A1 (en) * 2011-04-12 2012-10-18 Plus Chemicals Sa Solid state forms of cabazitaxel and processes for preparation thereof
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
CN102336726B (zh) * 2011-09-30 2014-11-26 重庆泰濠制药有限公司 一种卡巴他赛的制备方法
US9772339B2 (en) * 2011-09-30 2017-09-26 Life Technologies Corporation Methods and systems for image analysis identification
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
WO2013065070A1 (en) * 2011-11-01 2013-05-10 Fresenius Kabi Encology Ltd. Amorphous form of cabazitaxel and process for its preparation
ES2716799T3 (es) * 2011-11-28 2019-06-17 Fresenius Kabi Oncology Ltd Forma cristalina de cabazitaxel y proceso para la preparación de la misma
EP2791122B1 (en) * 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9394266B2 (en) 2012-03-08 2016-07-19 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (en) * 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN103058960B (zh) 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法

Also Published As

Publication number Publication date
CA2909500A1 (en) 2014-01-30
JP2015518012A (ja) 2015-06-25
CN102746258A (zh) 2012-10-24
AU2016200343A1 (en) 2016-02-11
EP2835369A1 (en) 2015-02-11
AU2016200343B2 (en) 2017-03-30
CA2870569A1 (en) 2014-01-30
IN2014MN01962A (enExample) 2015-07-10
EP2835369A4 (en) 2015-12-02
AU2013295924B2 (en) 2016-02-18
US9353076B2 (en) 2016-05-31
CN102746258B (zh) 2015-02-04
EP2835369B1 (en) 2019-04-03
EP3067348A1 (en) 2016-09-14
JP6329135B2 (ja) 2018-05-23
AU2013295924A1 (en) 2014-10-23
WO2014015760A1 (zh) 2014-01-30
US20150141674A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
CA2909500C (en) Crystal form of cabazitaxel and preparation method thereof
AU2012306057B2 (en) Crystalline forms of cabazitaxel
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
KR101917557B1 (ko) 3,5-2치환 벤젠알키닐 화합물의 결정
CN113698356A (zh) 新型parp抑制剂的稳定晶型及其制备方法
US11639341B2 (en) Crystal form of tipifarnib and method of treatment thereof
JP2019526570A (ja) アンドロゲン受容体拮抗薬の結晶形及びその製造方法並びに用途
US10118932B2 (en) Solid state forms of spiro-oxindole compounds
WO2012160568A1 (en) Process for preparing docetaxel trihydrate polymorph
AU2014339222B2 (en) A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
AU2014371150A1 (en) Crystals (2) of pyrazino[2,1-c][1,2,4]triazine compound
RU2712169C2 (ru) Новые полиморфные формы икотиниба фосфата и их применения
WO2017042837A2 (en) Stable crystalline form of regadenoson
CN104513201B (zh) 马来酸匹杉琼的结晶
WO2015074281A1 (zh) 力格赛狄盐及其晶型、它们的制备方法和用途
WO2023202651A1 (en) Polymorphic forms of glutamine antagonist and uses thereof
WO2018051239A1 (en) Process for the preparation of pure and stable crystalline raltegravir potassium form 3
CN107629048B (zh) 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法
CA3034535A1 (en) Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
CN103664836B (zh) 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
CN103819428B (zh) 7β,10β-二甲氧基多西紫杉醇的溶剂化物的晶型及其制备方法
WO2019001325A1 (zh) 雷西纳得的晶型xv及其制备方法
WO2011066735A1 (en) An Amorolfine HCl Crystal and the Preparation thereof
CN103910698A (zh) 卡巴他赛丙酮合物及其结晶

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151021

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625